PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23190413-4	2013	This study was designed to analyze the association between the NAT-2 and CYP2E1 polymorphisms with the development of anti-TB drug-induced hepatotoxicity (ATDH).	Terbium	123-125	N-acetyltransferase 2	Homo sapiens	63-68	
18023090-4	2007	RESULTS: Statistical analysis revealed that the frequency of a variant haplotype, NAT2 6A, was significantly increased in TB patients with hepatotoxicity, compared with those without hepatotoxicity [P = 0.001, odds ratio (OR) = 3.535].	Terbium	122-124	N-acetyltransferase 2	Homo sapiens	82-86	
19891553-9	2009	CONCLUSION: These findings suggest that genetic variants in the promoter and exons of NAT2 increase the risk of anti-TB drug-induced hepatitis by modifying acetylation phenotypes and/or gene expression of NAT2, and there is no essential role for genetic mutation of the other metabolizing enzymes in the development of this adverse reaction.	Terbium	117-119	N-acetyltransferase 2	Homo sapiens	86-90	
19891553-9	2009	CONCLUSION: These findings suggest that genetic variants in the promoter and exons of NAT2 increase the risk of anti-TB drug-induced hepatitis by modifying acetylation phenotypes and/or gene expression of NAT2, and there is no essential role for genetic mutation of the other metabolizing enzymes in the development of this adverse reaction.	Terbium	117-119	N-acetyltransferase 2	Homo sapiens	205-209	
18023090-7	2007	CONCLUSION: The present study shows that NAT2 is one of the determinants of anti-TB drug-induced hepatotoxicity.	Terbium	81-83	N-acetyltransferase 2	Homo sapiens	41-45	
18023090-8	2007	Moreover, the haplotypes, NAT2 4 and NAT2 6A, are useful new biomarkers for predicting anti-TB drug-induced hepatotoxicity.	Terbium	92-94	N-acetyltransferase 2	Homo sapiens	26-30	
18023090-8	2007	Moreover, the haplotypes, NAT2 4 and NAT2 6A, are useful new biomarkers for predicting anti-TB drug-induced hepatotoxicity.	Terbium	92-94	N-acetyltransferase 2	Homo sapiens	37-41	
29788627-0	2007	NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients.	Terbium	88-90	N-acetyltransferase 2	Homo sapiens	0-4	
32626768-1	2020	One of the well-studied phase II drug metabolizing enzymes is N-acetyltransferase 2 (NAT2) which has an essential role in the detoxification and metabolism of several environmental toxicants and many therapeutic drugs like isoniazid (antituberculosis, TB) and antimicrobial sulfonamides.	Terbium	252-254	N-acetyltransferase 2	Homo sapiens	62-83	
32626768-1	2020	One of the well-studied phase II drug metabolizing enzymes is N-acetyltransferase 2 (NAT2) which has an essential role in the detoxification and metabolism of several environmental toxicants and many therapeutic drugs like isoniazid (antituberculosis, TB) and antimicrobial sulfonamides.	Terbium	252-254	N-acetyltransferase 2	Homo sapiens	85-89	
30047605-1	2018	AIMS: The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment (AT-DILI).	Terbium	167-169	N-acetyltransferase 2	Homo sapiens	77-103	
30047605-1	2018	AIMS: The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment (AT-DILI).	Terbium	167-169	N-acetyltransferase 2	Homo sapiens	105-109	
27340556-3	2016	Previous reports in several populations have consistently demonstrated an association between polymorphisms in the N-acetyltransferase 2 (NAT2) gene, which is responsible for INH hepatic metabolism, and a risk of DILI in TB patients.	Terbium	221-223	N-acetyltransferase 2	Homo sapiens	115-136	
27340556-3	2016	Previous reports in several populations have consistently demonstrated an association between polymorphisms in the N-acetyltransferase 2 (NAT2) gene, which is responsible for INH hepatic metabolism, and a risk of DILI in TB patients.	Terbium	221-223	N-acetyltransferase 2	Homo sapiens	138-142	
27340556-8	2016	The findings demonstrated that slow NAT2 acetylator status is a significant predictor of the risk of DILI by anti-TB agents, and a personalized anti-TB treatment approach may aid in making treatment decisions and reducing the incidence of DILI.	Terbium	114-116	N-acetyltransferase 2	Homo sapiens	36-40